KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZN) Net Margin (2016 - 2025)

Historic Net Margin for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to 17.87%.

  • Astrazeneca's Net Margin rose 77900.0% to 17.87% in Q4 2025 from the same period last year, while for Dec 2025 it was 21.99%, marking a year-over-year increase of 67100.0%. This contributed to the annual value of 22.0% for FY2025, which is 89900.0% up from last year.
  • Latest data reveals that Astrazeneca reported Net Margin of 17.87% as of Q4 2025, which was up 77900.0% from 16.95% recorded in Q3 2025.
  • Astrazeneca's 5-year Net Margin high stood at 1083.54% for Q4 2022, and its period low was 20.09% during Q3 2021.
  • Over the past 5 years, Astrazeneca's median Net Margin value was 17.07% (recorded in 2024), while the average stood at 119.07%.
  • In the last 5 years, Astrazeneca's Net Margin skyrocketed by 10897600bps in 2022 and then tumbled by -10687300bps in 2023.
  • Over the past 5 years, Astrazeneca's Net Margin (Quarter) stood at 6.22% in 2021, then skyrocketed by 17522bps to 1083.54% in 2022, then plummeted by -99bps to 14.81% in 2023, then tumbled by -32bps to 10.07% in 2024, then surged by 77bps to 17.87% in 2025.
  • Its last three reported values are 17.87% in Q4 2025, 16.95% for Q3 2025, and 24.6% during Q2 2025.